BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21298367)

  • 1. Central nervous system relapse in CD56+, FLT3/ITD+ promyelocytic leukemia.
    Colovic N; Tomin D; Vidovic A; Tosic N; Atkinson HD; Colovic MD
    Med Oncol; 2012 Mar; 29(1):260-2. PubMed ID: 21298367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid.
    Burry LD; Seki JT
    Ann Pharmacother; 2002 Dec; 36(12):1900-6. PubMed ID: 12452754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
    Gallagher RE; Moser BK; Racevskis J; Poiré X; Bloomfield CD; Carroll AJ; Ketterling RP; Roulston D; Schachter-Tokarz E; Zhou DC; Chen IM; Harvey R; Koval G; Sher DA; Feusner JH; Tallman MS; Larson RA; Powell BL; Appelbaum FR; Paietta E; Willman CL; Stock W
    Blood; 2012 Sep; 120(10):2098-108. PubMed ID: 22734072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
    Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
    Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Testa U; Lo-Coco F
    Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia.
    Castagnola C; Elena C; Merli M
    Haematologica; 2008 Feb; 93(2):e28. PubMed ID: 18245644
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Esnault C; Rahmé R; Rice KL; Berthier C; Gaillard C; Quentin S; Maubert AL; Kogan S; de Thé H
    Blood; 2019 Mar; 133(13):1495-1506. PubMed ID: 30674471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide.
    Baba SM; Shah ZA; Pandith AA; Dil-Afroze ; Jan A; Mir KA; Aziz SA; Ahmad Z
    Cancer Genet; 2019 Feb; 231-232():14-21. PubMed ID: 30803552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute promyelocytic leukemia presenting with central nervous system involvement: a report of 2 cases.
    Ji M; Chi HS; Jang S; Park CJ; Lee JH; Seo JJ
    Korean J Lab Med; 2011 Jan; 31(1):9-12. PubMed ID: 21239864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.
    Diverio D; Rossi V; Avvisati G; De Santis S; Pistilli A; Pane F; Saglio G; Martinelli G; Petti MC; Santoro A; Pelicci PG; Mandelli F; Biondi A; Lo Coco F
    Blood; 1998 Aug; 92(3):784-9. PubMed ID: 9680345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
    Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K
    Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.
    Noguera NI; Breccia M; Divona M; Diverio D; Costa V; De Santis S; Avvisati G; Pinazzi MB; Petti MC; Mandelli F; Lo Coco F
    Leukemia; 2002 Nov; 16(11):2185-9. PubMed ID: 12399960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid involvement in acute promyelocytic leukaemia at presentation.
    Mishra J; Gupta M
    BMJ Case Rep; 2015 Mar; 2015():. PubMed ID: 25754165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases.
    Liso V; Specchia G; Pogliani EM; Palumbo G; Mininni D; Rossi V; Teruzzi E; Mestice A; Coppi MR; Biondi A
    Cancer; 1998 Oct; 83(8):1522-8. PubMed ID: 9781945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central nervous system relapse in a patient with acute promyelocytic leukaemia: does the risk stratification matter?
    Sahin DG; Gunduz E; Akay OM; Gulbas Z
    BMJ Case Rep; 2013 Jun; 2013():. PubMed ID: 23749823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
    Sobas M; Montesinos P; Boluda B; Bernal T; Vellenga E; Nomdedeu J; González-Campos J; Chillón M; Holowiecka A; Esteve J; Bergua J; González-Sanmiguel JD; Gil-Cortes C; Tormo M; Salamero O; Manso F; Fernández I; de la Serna J; Moreno MJ; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA;
    Leuk Lymphoma; 2019 Apr; 60(4):1030-1035. PubMed ID: 30322324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy.
    Ding W; Li YP; Nobile LM; Grills G; Carrera I; Paietta E; Tallman MS; Wiernik PH; Gallagher RE
    Blood; 1998 Aug; 92(4):1172-83. PubMed ID: 9694705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene.
    Yoo SJ; Park CJ; Jang S; Seo EJ; Lee KH; Chi HS
    Leuk Lymphoma; 2006 Sep; 47(9):1788-93. PubMed ID: 17064989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
    Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
    Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.